These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10831488)

  • 41. In vivo serotonin 5-HT(2A) receptor occupancy and quetiapine.
    Jones HM; Travis MJ; Mulligan R; Visvikis D; Gacinovic S; Ell PJ; Kerwin RW; Pilowsky LS
    Am J Psychiatry; 2000 Jan; 157(1):148. PubMed ID: 10618043
    [No Abstract]   [Full Text] [Related]  

  • 42. Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5-HT2 receptor occupancy studies and clinical response.
    Nyberg S; Nakashima Y; Nordström AL; Halldin C; Farde L
    Br J Psychiatry Suppl; 1996 May; (29):40-4. PubMed ID: 8733822
    [No Abstract]   [Full Text] [Related]  

  • 43. Effects of aging on 5-HT(2A) R binding: a HRRT PET study with and without partial volume corrections.
    Uchida H; Chow TW; Mamo DC; Kapur S; Mulsant BH; Houle S; Pollock BG; Graff-Guerrero A
    Int J Geriatr Psychiatry; 2011 Dec; 26(12):1300-8. PubMed ID: 21351153
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Parametric PET imaging of 5HT2A receptor distribution with 18F-setoperone in the normal human neocortex.
    Petit-Taboué MC; Landeau B; Barré L; Onfroy MC; Noël MH; Baron JC
    J Nucl Med; 1999 Jan; 40(1):25-32. PubMed ID: 9935052
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Test-retest variability of high resolution positron emission tomography (PET) imaging of cortical serotonin (5HT2A) receptors in older, healthy adults.
    Chow TW; Mamo DC; Uchida H; Graff-Guerrero A; Houle S; Smith GS; Pollock BG; Mulsant BH
    BMC Med Imaging; 2009 Jul; 9():12. PubMed ID: 19580676
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis, affinity and specificity of 18F-setoperone, a potential ligand for in-vivo imaging of cortical serotonin receptors.
    Maziere B; Crouzel C; Venet M; Stulzaft O; Sanz G; Ottaviani M; Sejourne C; Pascal O; Bisserbe JC
    Int J Rad Appl Instrum B; 1988; 15(4):463-8. PubMed ID: 3255742
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of rapid tryptophan depletion on brain 5-HT(2) receptors: a PET study.
    Yatham LN; Liddle PF; Shiah IS; Lam RW; Adam MJ; Zis AP; Ruth TJ
    Br J Psychiatry; 2001 May; 178():448-53. PubMed ID: 11331561
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The current status of PET scanning with respect to schizophrenia.
    Sedvall G
    Neuropsychopharmacology; 1992 Aug; 7(1):41-54. PubMed ID: 1388021
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High-resolution SPECT study of regional cerebral blood flow in drug-free and drug-naive schizophrenic patients.
    Vita A; Bressi S; Perani D; Invernizzi G; Giobbio GM; Dieci M; Garbarini M; Del Sole A; Fazio F
    Am J Psychiatry; 1995 Jun; 152(6):876-82. PubMed ID: 7755117
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone.
    Blin J; Baron JC; Dubois B; Crouzel C; Fiorelli M; Attar-Lévy D; Pillon B; Fournier D; Vidailhet M; Agid Y
    Brain; 1993 Jun; 116 ( Pt 3)():497-510. PubMed ID: 8513389
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neuroendocrine effects of setoperone: a new neuroleptic drug.
    Meco G; Lestingi L; Buzzi MG; Petrini P; Pasqualoni V; Falaschi P; Marini S
    Int J Clin Pharmacol Res; 1986; 6(6):465-8. PubMed ID: 2879803
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action.
    Reynolds GP; Rossor MN; Iversen LL
    J Neural Transm Suppl; 1983; 18():273-7. PubMed ID: 6135746
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recent developments in PET scan imaging of neuroreceptors in schizophrenia.
    Sedvall G; Pauli S; Farde L; Karlsson P; Nyberg S; Nordström AL
    Isr J Psychiatry Relat Sci; 1995; 32(1):22-9. PubMed ID: 7622344
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The involvement of 5-HT1a serotonin receptors in the pathophysiology and pharmacotherapy of schizophrenia].
    Maćkowiak M; Czyrak A; Wedzony K
    Psychiatr Pol; 2000; 34(4):607-21. PubMed ID: 11059260
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is desire for social relationships mediated by the serotonergic system in the prefrontal cortex? An [(18)F]setoperone PET study.
    Gerretsen P; Graff-Guerrero A; Menon M; Pollock BG; Kapur S; Vasdev N; Houle S; Mamo D
    Soc Neurosci; 2010; 5(4):375-83. PubMed ID: 20198536
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Positron emission tomography studies of abnormal glucose metabolism in schizophrenia.
    Buchsbaum MS; Hazlett EA
    Schizophr Bull; 1998; 24(3):343-64. PubMed ID: 9718628
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relationship between central and peripheral serotonin 5-HT2A receptors: a positron emission tomography study in healthy individuals.
    Cho R; Kapur S; Du L; Hrdina P
    Neurosci Lett; 1999 Feb; 261(3):139-42. PubMed ID: 10081968
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Blood-cerebrospinal fluid and blood-brain barriers imaged by 18F-labeled metabolites of 18F-setoperone studied in humans using positron emission tomography.
    Blin J; Crouzel C
    J Neurochem; 1992 Jun; 58(6):2303-10. PubMed ID: 1573409
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of serotonin 5-HT(2A) receptors in the human cerebellum and alterations in schizophrenia.
    Eastwood SL; Burnet PW; Gittins R; Baker K; Harrison PJ
    Synapse; 2001 Nov; 42(2):104-14. PubMed ID: 11574947
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vivo neuropharmacology of schizophrenia.
    Bigliani V; Pilowsky LS
    Br J Psychiatry Suppl; 1999; (38):23-33. PubMed ID: 10884897
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.